GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovaQor Inc (OTCPK:INQR) » Definitions » ROE %

INQR (InnovaQor) ROE % : 0.00% (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is InnovaQor ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. InnovaQor's annualized net income for the quarter that ended in Sep. 2023 was $-1.36 Mil. InnovaQor's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-14.94 Mil. Therefore, InnovaQor's annualized ROE % for the quarter that ended in Sep. 2023 was N/A%.

The historical rank and industry rank for InnovaQor's ROE % or its related term are showing as below:

INQR's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.03
* Ranked among companies with meaningful ROE % only.

InnovaQor ROE % Historical Data

The historical data trend for InnovaQor's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovaQor ROE % Chart

InnovaQor Annual Data
Trend Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Dec21 Dec22
ROE %
Get a 7-Day Free Trial - - - - -

InnovaQor Quarterly Data
Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InnovaQor's ROE %

For the Health Information Services subindustry, InnovaQor's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovaQor's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovaQor's ROE % distribution charts can be found below:

* The bar in red indicates where InnovaQor's ROE % falls into.



InnovaQor ROE % Calculation

InnovaQor's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-1.614/( (-12.129+-13.693)/ 2 )
=-1.614/-12.911
=N/A %

InnovaQor's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-1.356/( (-14.774+-15.113)/ 2 )
=-1.356/-14.9435
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


InnovaQor  (OTCPK:INQR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-1.356/-14.9435
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.356 / 0.608)*(0.608 / 0.082)*(0.082 / -14.9435)
=Net Margin %*Asset Turnover*Equity Multiplier
=-223.03 %*7.4146*N/A
=ROA %*Equity Multiplier
=-1653.68 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-1.356/-14.9435
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.356 / -1.356) * (-1.356 / -1.388) * (-1.388 / 0.608) * (0.608 / 0.082) * (0.082 / -14.9435)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9769 * -228.29 % * 7.4146 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


InnovaQor ROE % Related Terms

Thank you for viewing the detailed overview of InnovaQor's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovaQor Business Description

Traded in Other Exchanges
N/A
Address
400 S. Australian Avenue, Suite 800, West Palm Beach, FL, USA, 33401
InnovaQor Inc provides information technology solutions and services to healthcare and laboratory customers in the United States. Its goal is to develop and deliver a technology-based medical professional's network communication platform to a broad range of healthcare professionals and businesses using a subscription revenue model with added value bolt-on services.
Executives
Francisco Iii Roca director 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Darrell L Peterson director, officer: Chief Executive Officer 2390 CIRCLE DRIVE, WEST PALM BEACH FL 33406
Sharon Lynne Hollis director 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Justin Doherty director 400 S. AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Thomas Joseph Bellante officer: Chief Financial Officer 14706 CROYDON PLACE, TAMPA FL 33618
Jayne Kirby officer: VP Finance 1035 LAURIER O., SUITE 200, MONTREAL A8 H2V 2L1
Arthur Gelston 10 percent owner 1035 LAURIER STREET WEST, MONTREAL A8 H2V 2L1
Visual Healthcare Corp 10 percent owner 790 ROCKLAND AVE., MONTREAL, QC. A8 H2V 2Z6
Philippe Rainville officer: CFO 391A LAURIER WEST, MONTREAL A8 H2V 2K3
Philippe Panzini director 391A LAURIER WEST, MONTREAL A8 H2V 2K3
Michel Maksud officer: VP Technology 391A LAURIER WEST, MONTREAL A8 H2V 2K3
Gerard Dab director, officer: CEO and Chairman of the Board 391A LAURIER WEST, MONTREAL A8 H2V 2K3
Louis J Lombardo director 108 SMITH LAKE ROAD, ROSCOE NY 12776
Visualmed Clinical Systems Corp 10 percent owner
Barry Scharf officer: VP Operations 391A LAURIER WEST, MONTREAL A8 H2V 2K3